

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)



(10) International Publication Number
WO 2022/140774 A1

(51) International Patent Classification:

C07K 14/725 (2006.01) *C12N 5/0783* (2010.01)
A61K 35/17 (2015.01) *G01N 33/569* (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2021/073057

(22) International Filing Date:

21 December 2021 (21.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/129,480 22 December 2020 (22.12.2020) US
63/170,196 02 April 2021 (02.04.2021) US

(71) Applicant: **NEOGENE THERAPEUTICS B.V.**
[NL/NL]; Science Park 106, 1098 XG Amsterdam (NL).

(72) Inventors: **LINNEMANN, Carsten**; Science Park 106, 1098 XG Amsterdam (NL). **KUILMAN, Thomas**; Science Park 106, 1098 XG Amsterdam (NL). **BENDLE, Gavin, M.**; Science Park 106, 1098 XG Amsterdam (NL). **VAN HEIJST, Jeroen, W.J.**; Science Park 106, 1098 XG Amsterdam (NL). **KONG, Xiangjun**; Science Park 106, 1098 XG Amsterdam (NL). **EGGERMONT, Lock, Josephus**; Science Park 106, 1098 XG Amsterdam (NL).

(74) Agent: **DELANEY, Karoline, A.**; KNOBBE, MARTENS, OLSON & BEAR, LLP, 2040 Main Street, 14th Floor, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PEPTIDE MARKERS TO TRACK GENETICALLY ENGINEERED CELLS

Figure 1. Diagram of TCR constant domain epitope.



(57) Abstract: To allow control over injected genetically engineered cells, it is helpful that the genetically engineered cells express a marker that can be used to detect such cells among a pool of unmodified cells. Some embodiments relate to a marked protein comprising a TCR constant domain and an exogenous amino acid variation that comprises a sequence that is detectable and identifiable within the TCR constant domain. Other embodiments relate to an antibody epitope that is attached to a TCR chain. Both the marked proteins and the antibody epitopes can be used to track genetically engineered cells.

WO 2022/140774 A1